Growth Differentiation Factor (GDF)-15 Blocks Norepinephrine-induced Myocardial Hypertrophy via a Novel Pathway Involving Inhibition of Epidermal Growth Factor Receptor Transactivation

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC

(2012) et al.   EUROPEAN HEART JOURNAL

The human sympathetic nervous system: its relevance in hypertension and heart failure

(2012) G. Parati et al.   EUROPEAN HEART JOURNAL

The Association of Growth Differentiation Factor-15 with Left Ventricular Hypertrophy in Hypertensive Patients

(2012) Hao Xue et al.   PLoS One

Relation of Growth-Differentiation Factor 15 to Left Ventricular Remodeling in ST-Segment Elevation Myocardial Infarction

(2011) Alberto Dominguez-Rodriguez et al.   AMERICAN JOURNAL OF CARDIOLOGY

Transactivated EGFR mediates α1-AR-induced STAT3 activation and cardiac hypertrophy

(2011) Yan Li et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside

(2011) Xinye Xu et al.   BIOMARKERS

Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy

(2011) Silvia Montoro-García et al.   European Journal of Internal Medicine

An endogenous brake on the sympathetic nervous system

(2011) Giuseppe Schillaci et al.   Journal of Cardiovascular Medicine

Spinophilin is required for normal morphology, Ca2+ homeostasis and contraction but dispensable for β-adrenergic stimulation of adult cardiomyocytes

(2011) Daria Petzhold et al.   JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY

Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)—possible therapeutic perspectives

(2011) Federico Cacciapuoti   Journal of the American Society of Hypertension

GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice

(2011) Tibor Kempf et al.   NATURE MEDICINE

Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects

(2011) Kai M. Eggers et al.   SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION

Growth differentiation factor 15 in different stages of heart failure: potential screening implications

(2010) Fangfang Wang et al.   BIOMARKERS

Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure

(2010) Inder S. Anand et al.   CIRCULATION

Growth-Differentiation Factor-15 for Long-Term Risk Prediction in Patients Stabilized After an Episode of Non–ST-Segment–Elevation Acute Coronary Syndrome

(2009) Kai M. Eggers et al.   Circulation-Cardiovascular Genetics

The haplotype of the growth-differentiation factor 15 gene is associated with left ventricular hypertrophy in human essential hypertension

(2009) Xiaojian Wang et al.   CLINICAL SCIENCE

Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction

(2009) S. Q. Khan et al.   EUROPEAN HEART JOURNAL

Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study

(2009) L. Lind et al.   EUROPEAN HEART JOURNAL

MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets

(2008) Anthony J. Muslin   CLINICAL SCIENCE

Alterations in circulating activin A, GDF-15, TGF-β3 and MMP-2, -3, and -9 during one year of left ventricular reverse remodelling in patients operated for severe aortic stenosis

(2008) Johannes L. Bjørnstad et al.   EUROPEAN JOURNAL OF HEART FAILURE